Volume 18, Number 1—January 2012
Letter
Mycobacterium riyadhense Pulmonary Infection, France and Bahrain
, Hélène Marchandin, Anne-Laure Michon, Mikael Ponsada, Georges Chyderiotis, Patrick Brisou, Abdul Bhat, and Gilles PanteixTable
Clinical characteristics, drug susceptibility testing, and outcome for 3 case-patients with Mycobacterium riyadhense infection, France and Bahrain*
| Patient age, y/sex | Clinical situation | Molecular-based identification of M. riyadhense |
Drug susceptibility pattern, drug (MIC, µg/mL) interpretation | Antimicrobial drug therapy | Treatment duration, outcome | ||
|---|---|---|---|---|---|---|---|
| Gene | % Sequence similarity with type strain | GenBank accession nos. | |||||
| 19/M† |
Bone infection in left maxillary sinus |
16S rRNA, rpoB, hsp65 |
Type strain |
EU27464, FJ786256, EU921671 |
AMK (10.0) R; CYC (20.0) S; CIP (2.0) S; CLF (<0.5) S; CLR (<2.0) S; EMB (5.0) S; INH (1.0) I; PAS (>1.0) R; PRO (<1.0) S; RFB (0.2) S; RIF (0.2) S; STR (5.0) S‡ |
INH, RFP, EMB; then INH, RFP |
9 mo, cured |
| 39/F§ |
Pulmonary infection |
16S rRNA¶, rpoB, hsp65 |
99.8, 99.8, 100 |
JF896094, JF896096, JF896098 |
AMK (<1.0) S; CIP (1.0) S; CLR (0.12) S; DOX (16.0) R; EMB (<0.5) S; ETH (0.3) S; INH (0.5) S; LZD (<1.0) S; MOX (<0.12) S; RFB (<0.25) S; RIF (<0.12) S; STR (1.0) S; TMP/SMX (<0.12/2.38) NA# |
INH, RFP, EMB, PZA; then INH, RFP |
1 y, cured |
| 43/M** | Pulmonary infection | 16S rRNA¶, rpoB, hsp65 | 99.8, 99.7, 99.1 | JF896095, JF896097, JF896099 | AMK (<1.0) S; CIP (0.12) S; CLR (0.12) S; EMB (<0.5) S; ETH (0.3) S; DOX (4.0) R; INH (0.25) S; LZD (<1.0) S; MOX (<0.12) S; RFB (<0.25) S; RIF (<0.12) S; STR (<0.5) S; TMP/SMX (<2.0/38.0) NA# | CLR, CIP; then INH, RFP, EMB, PZA, CLR, CIP; then INH, RFP, CLR, CIP | 1 y, relapse; 8 mo, cured |
*AMK, amikacin; R, resistant; CYC, cycloserine; S, susceptible; CIP, ciprofloxacin; CLF, clofazimine; CLR, clarithromycin; EMB, ethambutol; INH, isoniazid; I, intermediate; PAS, para-aminosalicylate sodium; PRO, prothionamide; RFB, rifabutin; RIF, rifampin; STR, streptomycin ; RFP, rifapentine; DOX, doxycycline; ETH, ethionamide; LZD, linezolid; MOX, moxifloxacin; TMP/SMX, trimethoprim/sulfamethoxazole; NA, not available; PZA, pyrazinamide.
†Patient in Saudi Arabia; reported by van Ingen et al. (1).
‡Drug susceptibility testing was performed by using the agar dilution method.
§Patient in France.
¶Low 16S rRNA gene polymorphism between several mycobacterial species.
#Drug susceptibility testing was performed by using broth microdilution panels (SLOMYCO Sensititer; Trek Diagnosis Systems, Cleveland< OH, USA) and interpreted according to standards of the National Committee for Clinical Laboratory Standards (3).
**Patient in Bahrain.
